Pasithea Therapeutics Corp (KTTA)
NASDAQ:KTTA
Want to see KTTA full AI Analyst Report?
Total Valuation
Pasithea Therapeutics Corp has a market cap or net worth of $24.13M. The enterprise value is -$50.40B.
Market Cap$24.13M
Enterprise Value-$50.40B
Share Statistics
Pasithea Therapeutics Corp has 33,414,448 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33,414,448
Owned by Insiders1.49%
Owned by Institutions35.96%
Financial Efficiency
Pasithea Therapeutics Corp’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -37.74%.
Return on Equity (ROE)-0.37
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-37.74%
Return on Capital Employed (ROCE)-0.38
Revenue Per Employee0.00
Profits Per Employee-5.11B
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Pasithea Therapeutics Corp is ―. Pasithea Therapeutics Corp’s PEG ratio is 0.00576.
PE Ratio―
PS Ratio0.00
PB Ratio0.16
Price to Fair Value0.16
Price to FCF>-0.01
Price to Operating Cash Flow-1.04
PEG Ratio0.00576
Income Statement
In the last 12 months, Pasithea Therapeutics Corp had revenue of 0.00 and earned -20.43M in profits. Earnings per share was -2.91.
Revenue0.00
Gross Profit0.00
Operating Income-20.86M
Pretax Income-20.43M
Net Income-20.43M
EBITDA-20.19M
Earnings Per Share (EPS)-2.91
Cash Flow
In the last 12 months, operating cash flow was -16.94M and capital expenditures 1.00, giving a free cash flow of -16.94M billion.
Operating Cash Flow-16.94M
Free Cash Flow-16.94M
Free Cash Flow per Share-0.51
Dividends & Yields
Pasithea Therapeutics Corp pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta4.01
52-Week Price Change-22.37%
50-Day Moving Average0.77
200-Day Moving Average0.82
Relative Strength Index (RSI)42.05
Average Volume (3m)98.68K
Important Dates
Pasithea Therapeutics Corp upcoming earnings date is Mar 30, 2022, After Close (Confirmed).
Last Earnings DateInvalid Date
Next Earnings DateMar 30, 2022
Ex-Dividend Date―
Financial Position
Pasithea Therapeutics Corp as a current ratio of 11.35, with Debt / Equity ratio of 0.00%
Current Ratio11.35
Quick Ratio11.35
Debt to Market Cap0.00
Net Debt to EBITDA2.73
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Pasithea Therapeutics Corp has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Pasithea Therapeutics Corp EV to EBITDA ratio is 2.28, with an EV/FCF ratio of <0.01.
EV to Sales0.00
EV to EBITDA2.28
EV to Free Cash Flow<0.01
EV to Operating Cash Flow<0.01
Balance Sheet
Pasithea Therapeutics Corp has $50.40B in cash and marketable securities with $0.00 in debt, giving a net cash position of $50.40B billion.
Cash & Marketable Securities$50.40B
Total Debt$0.00
Net Cash$50.40B
Net Cash Per Share$1.51K
Tangible Book Value Per Share$7.32
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Pasithea Therapeutics Corp is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$3.00
Price Target Upside305.41% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast80.42%